Liver Disease and HIV: Study Reveals Major Gaps in Liver Fibrosis Screening and Offers a Promising Solution
4 Articles
4 Articles
Liver disease and HIV: Study reveals major gaps in liver fibrosis screening and offers a promising solution
Thanks to antiretroviral therapy and improved control of viral hepatitis (HBV and HCV), people living with HIV generally live longer and healthier lives. However, liver disease remains common in this population and is one of the leading causes of death.
People living with HIV are more at risk of developing liver disease, and this is one of the leading causes of death in this population. The traditional test does not detect several cases of liver fibrosis in people living with HIV. The McGill University Health Centre Research Institute has developed a new, more effective tool.
Researchers from the Molecular Metabolism Group of the Universidade de Santiago de Compostela (USC), led by Rubén Nogueiras from the Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), have identified new therapeutic possibilities for Resmetirom, the only drug currently approved for the treatment of hepatic fibrosis associated with steatotic liver disease linked to metabolic dysfunction (MASLD).
Or CiMUS discovery about or Resmetiron will allow to develop dirixid therapies specifically against this infermidade no future Or artigo A team of USC reveals novas therapeutic options do sole drug against a hepatic fibrous publicuse primeiro in GCiencia.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
